Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 25Multiple Myeloma 13Prostatic Neoplasms 10Osteoporosis 8Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 5Fractures, Bone 4Neoplasms, Plasma Cell 3Lymphoma 3Bone Diseases, Metabolic 3Bone Diseases 3Spinal Cord Compression 2Pain 2Ovarian Neoplasms 2Osteosarcoma 2Lung Neoplasms 2Kidney Neoplasms 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Bone Neoplasms 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Pleural Effusion, Malignant 1Paraproteinemias 1Oligodendroglioma 1Neoplastic Processes 1Neoplastic Cells, Circulating 1Neoplasms 1Nasopharyngeal Neoplasms 1

Interventions

prexasertib 1Zoledronic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hereditary Breast and Ovarian Cancer Syndrome × Zoledronic Acid × Clear all
NCT00305695 2020-03-24

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

GOG Foundation

Phase 2 Completed
160 enrolled 10 charts
BreastGynecologic

Osteoporosis, Ovarian Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡